Alnylam CEO: Novartis' cuts to RNAi a 'miserable predictor' of success
April 16, 2014 at 14:07 PM EDT
A decision by drug giant Novartis to cut back on its research into a field of drugs known as RNA interference has been cited as spurring a selloff at Cambridge biotech Alnylam Pharmaceuticals...